Sanofi (SNY) Stock Price, News & Analysis

Company Overview

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Key Stats

• Today's Range: $54.58 to $55.77
• 50-Day Range: $52.37 to $59.42
• 52-Week Range: $45.22 to $60.12
• Volume: 1.84 million shs
• Average Volume: 2.27 million shs
• Market Capitalization: $138.62 billion
• P/E Ratio: 21.94
• Dividend Yield: 2.69%
• Price Target: $62.50
• Consensus Rating: Buy

Sanofi Stock Analysis - MarketRank™

Sanofi scored higher than 66% of companies evaluated by MarketBeat, and ranked 317th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Buy

Consensus Rating

Sanofi has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Sanofi has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 8.94%

Earnings Growth

Earnings for Sanofi are expected to grow by 8.94% in the coming year, from $4.36 to $4.75 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Sanofi is 21.94, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.62.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sanofi is 21.94, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.23.

Price to Earnings Growth Ratio

Sanofi has a PEG Ratio of 1.01. PEG Ratios around 1 indicate that a company is correctly valued.

Price to Book Value per Share Ratio

Sanofi has a P/B Ratio of 1.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.23% of the float of Sanofi has been sold short.

Short Interest Ratio / Days to Cover

Sanofi has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sanofi has recently increased by 3.51%, indicating that investor sentiment is decreasing.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Sanofi pays a meaningful dividend of 2.69%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Sanofi does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Sanofi is 59.04%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Sanofi will have a dividend payout ratio of 30.95% next year. This indicates that Sanofi will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.23% of the float of Sanofi has been sold short.

Short Interest Ratio / Days to Cover

Sanofi has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sanofi has recently increased by 3.51%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 4.0 / 5
• News Sentiment: 1.15

News Sentiment

Sanofi has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 29 news articles for Sanofi this week, compared to 15 articles on an average week.

Search Interest

7 people have searched for SNY on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.

MarketBeat Follows

11 people have added Sanofi to their MarketBeat watchlist in the last 30 days. This is an increase of 267% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sanofi insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.00% of the stock of Sanofi is held by insiders.

Percentage Held by Institutions

Only 14.04% of the stock of Sanofi is held by institutions.

SNY Stock Analysis - Frequently Asked Questions

How have SNY shares performed this year?

Sanofi's stock was trading at $48.23 at the beginning of the year. Since then, SNY stock has increased by 13.2% and is now trading at $54.62.
View the best growth stocks for 2025 here.

How were Sanofi's earnings last quarter?

Sanofi (NASDAQ:SNY) posted its quarterly earnings results on Thursday, January, 30th. The company reported $0.70 earnings per share for the quarter, meeting analysts' consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a trailing twelve-month return on equity of 25.61%.

Does Sanofi have any subsidiaries?

The following companies are subsidiaries of Sanofi: Kiadis Pharma, Principia BioPharma, Synthorx, Ablynx, Bioverativ, Aventis S.A., Ablynx N.V., and more.

Who are Sanofi's major shareholders?

Sanofi's top institutional investors include First Hawaiian Bank, Central Pacific Bank Trust Division, Versant Capital Management Inc and Marcum Wealth LLC.
View institutional ownership trends.

How do I buy shares of Sanofi?

Shares of SNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Sanofi own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sanofi investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR).

Company Calendar

• Last Earnings: 1/30/2025
• Today: 4/03/2025
• Next Earnings (Estimated): 4/24/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SNY
• CIK: 1121404
• Web: www.sanofi.com
• Phone: (315) 377-4000
• Fax: 33-1-53-77-43-03
• Employees: 91,600
• Year Founded: 2004

Price Target and Rating

• Average Stock Price Target: $62.50
• High Stock Price Target: $65.00
• Low Stock Price Target: $60.00
• Potential Upside/Downside: +14.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $2.49
• Trailing P/E Ratio: 21.94
• Forward P/E Ratio: 12.53
• P/E Growth: 1.01
• Net Income: $6.02 billion
• Net Margins: 12.77%
• Pretax Margin: 15.12%
• Return on Equity: 25.61%
• Return on Assets: 14.72%

Debt

• Debt-to-Equity Ratio: 0.15
• Current Ratio: 1.46
• Quick Ratio: 1.14

Sales & Book Value

• Annual Sales: $44.29 billion
• Price / Sales: 3.13
• Cash Flow: $5.38 per share
• Price / Cash Flow: 10.16
• Book Value: $33.20 per share
• Price / Book: 1.65

Miscellaneous

• Outstanding Shares: 2,537,845,000
• Free Float: 2,512,467,000
• Market Cap: $138.62 billion
• Optionable: Optionable
• Beta: 0.58